Serum KL-6 levels in lung cancer patients with or without interstitial lung disease

Journal of Clinical Laboratory Analysis

Volumn 24, Issue 5, 2010, Pages 295-299

  Miyazaki, Kunihiko ^a,b   Kurishima, Koichi ^b   Kagohashi, Katsunori ^b   Kawaguchi, Mio ^b   Ishikawa, Hiroichi ^a   Satoh, Hiroaki ^b   Hizawa, Nobuyuki ^b  

^a Tsukuba Medical Center   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Interstitial lung disease; KL 6; Lung cancer

Indexed keywords

GLYCOPROTEIN; KL 6; MUCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCIN-1; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 77957283021     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20404     Document Type: Article

References (22)

1. Mizushima Y, Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary .brosis. A review of Japanese cases. Chest 1995;108:1272-1277.
2. Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc 2002;77:763-770. (Pubitemid 34847718)
3. Ohyabu N, Hinou H, Matsushita T, et al. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. J Am Chem Soc 2009;131:17102-17109.
4. Oyama T, Kohno N, Yokoyama A, et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung 1997;175:379-385.
5. Takahashi T, Munakata M, Suzuki I, Kawakami Y. Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 1998;158: 1294-1298.
6. Fukaya S, Oshima H, Kato K, et al. KL-6 as a novel marker for activities of interstitial pneumonia in connective tissue diseases. Rheumatol Int 2000;19:223-225.
7. Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000;27:1164-1170. (Pubitemid 30262499)
8. Arai Y, Obinata K, Sato Y, et al. Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia. Eur J Pediatr 2001;160: 425-429.
9. Ohnshi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002;165:378-381.
10. Janssen R, Sato H, Grutters JC, et al. Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest 2003;124:2119-2125.
11. Kohno N, Akiyama M, Kyoizumi S, et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988;18:203-216.
12. World Health Organization. Histological Typing of Lung and Pleural Tumours. International Histological Classification of Tumours, third edition. Geneva: WHO; 1999.
13. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717. (Pubitemid 27260107)
14. Chiyo M, Sekine Y, Iwata T, et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: Analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 2003;126:1141-1146.
15. Miyazaki K, Satoh H, Kurishima K, et al. Impact of interstitial lung disease on survival for patients with non-small cell lung cancer. Anticancer Res 2009;29:2671-2674.
16. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: Geographical distribution and secular trends. J Thorac Oncol 2008;3:819-831.
17. Spiro SG, Tanner NT, Silvestri GA, et al. Lung cancer: Progress in diagnosis, staging and therapy. Respirology 2010;15:44-50.
18. Hinata N, Takemura T, Ikushima S, et al. Phenotype of regenerative epithelium in idiopathic interstitial pneumonias. J Med Dent Sci 2003;50:213-224.
19. Hara R, Itami J, Komiyama T, Katoh D, Kondo T. Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 2004;125:340-344.
20. Matsuno Y, Satoh H, Ishikawa H, et al. Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy. Med Oncol 2006;23:75-82.
21. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006;260:429-434. (Pubitemid 44571130)
22. Inata J, Hattori N, Yokoyama A, et al. Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma. Int J Cancer 2007;120:2643-2649.